Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > 14% of worst case scenario

<< Previous

Bullboard Posts

Next >>

Comment by RickyBobbyTOon May 13, 2022 12:52pm

103 Views

Post# 34682057

RE:14% of worst case scenario

At least he's pleased. I'm sure it's very pleasing. Could be years more of this pleasing before we see any data.

hmmmmmmmm wrote: The "worst case" scenario from the March 2022 Investor Update is: 0.5 patients enrolled-per site, per month. (page 10)

That is 7 patients each month.

Seto put out a statemnet this morning " we are pleased to report..." 4 patients over 3 months.

How can you be pleased by hitting only 14% of your "worst case scenario" goals?

This is not leadership.